Monitor Antimicrobial Resistance in Animal Health Pathogens through the National Animal Health Laboratory Network

Goal Leader(s):

Sarah Tomlinson, DVM, Associate Deputy Administrator, Strategy and Policy, APHIS Veterinary Services (VS)
Elizabeth Lautner, DVM, MS, Associate Deputy Administrator, Diagnostics and Biologics, APHIS VS
Goal Overview

Goal statement

- Establish a surveillance program within the National Animal Health Laboratory Network (NAHLN) to monitor antimicrobial resistance (AMR) profiles in animal pathogens to enhance the Nation’s early detection of, response to, and recovery from animal health emergencies, identify new or emerging AMR profiles, and help monitor continued usefulness of antimicrobials over time. By September 2023, USDA will establish a long-term AMR surveillance program with at least 30 laboratories participating annually.

Problem to Be Solved

- Antimicrobial resistance poses a threat to disease control throughout the world and is a primary concern for human and animal health.
- There is a gap in understanding of AMR patterns in bacteria that cause disease in animals and having national-level information on AMR in animal health pathogens is an important component of addressing AMR at the Federal level.

What Success Looks Like

- Collecting and providing AMR data via public-facing reports and dashboards will provide transparency to USDA’s efforts to address AMR and support USDA’s goal of ensuring America’s agricultural system is equitable, resilient, and prosperous by addressing threats to animal health posed by AMR.
- AMR data collected through the NAHLN AMR surveillance program will be utilized as a part of a unified Federal response when AMR profiles of concern are detected by a One Health partner agency (USDA, Food and Drug Administration (FDA), or Centers for Disease Control and Prevention).
- Clinicians will use the AMR data in making the best treatment decisions.
Goal target(s)

In the table below, please repeat the key metrics included in the goal statement (previous slide) that will be used to track progress.

Please update this column each quarter.

<table>
<thead>
<tr>
<th>Achievement statement</th>
<th>Key indicator(s)</th>
<th>Quantify progress</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repeat the achievement statement from the goal statement on the previous slide</td>
<td>A “key performance indicator” measures progress toward a goal target</td>
<td>These values enable us (and you!) to calculate % complete for any type of target*</td>
<td></td>
</tr>
<tr>
<td><strong>By...</strong></td>
<td><strong>We will...</strong></td>
<td><strong>Name of indicator</strong></td>
<td><strong>Target value</strong></td>
</tr>
<tr>
<td>12/31/2022</td>
<td>Monitor trends in AMR in animal pathogens, identify new or emerging AMR profiles, and help monitor continued usefulness of antimicrobials over time</td>
<td>Number of participating laboratories</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Number of isolates with antimicrobial susceptibility testing (AST) data</td>
<td>5,000/year</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Number of isolates with whole genome sequencing performed</td>
<td>500/year</td>
</tr>
</tbody>
</table>

* Even qualitative targets! If the target is to achieve a qualitative outcome, quantify progress this way: 1=“Yes, we achieved it”, 0=“No, not yet”

** As of 10/1/2021
<table>
<thead>
<tr>
<th>VS Strategy &amp; Policy (S&amp;P)</th>
<th>VS Diagnostics &amp; Biologics (D&amp;B)</th>
<th>Program and Policy Development (PPD)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Senior Lead</strong>: Sarah Tomlinson (Executive Champion)</td>
<td><strong>Senior Lead</strong>: Beth Lautner (D&amp;B Associate Deputy Administrator)</td>
<td><strong>Senior Lead</strong>: Eric Hoffman (Deputy Chief, Budget and Program Analysis, PPD)</td>
</tr>
<tr>
<td><strong>Team Lead</strong>: Chelsey Shivley (VS AMR Coordinator)</td>
<td><strong>Team Lead</strong>: Beth Harris (NAHLN Associate Coordinator)</td>
<td><strong>Team Leads</strong>: Allison Boehm (PPD Program Analyst), Shaun Luber (PPD Program Analyst)</td>
</tr>
</tbody>
</table>

**Agency Partners**: Participating NAHLN laboratories; FDA Center for Veterinary Medicine Veterinary Laboratory Investigation and Response Network (VetLIRN)
Goal Strategies

Strategies

• Laboratories will be provided the opportunity to enroll in this surveillance project annually during Q1 of each fiscal year, and they enroll for the upcoming calendar year. [There are 60 NAHLN laboratories; only 31 currently have the necessary equipment for AMR sampling. The NAHLN laboratories conduct testing for emergency programs including responding to outbreaks of highly pathogenic avian influenza; emergency needs may impact the number of participating laboratories or the level AMR sampling conducted.]

• Participating laboratories will submit antimicrobial susceptibility data to the NAHLN program on a monthly basis. The NAHLN program will use this data to update our external dashboard every month, providing near-real time information to the public.

• Whole genome sequencing data will be submitted to the NAHLN BioProject hosted through the National Institutes of Health National Center for Biotechnology Information (NCBI) on a quarterly basis, with uploaded data being released immediately for public use.
Key indicators

ANTIMICROBIAL SUSCEPTIBILITY TEST (AST) RESULTS - FY2022

No. AST | Cumulative total
--- | ---
962 | 962
880 | 1842
200 | 2000
Calendar year 2022 is the final year of the NAHLN AMR pilot surveillance program.

- 31 laboratories have been enrolled for Year 5 (January - December 2022).
- Over the next year, APHIS will gather stakeholder input for the transition to the long-term program and continue developing a public-facing dashboard to communicate ongoing surveillance data.
- Stakeholder meetings began February 15, 2022.

### Milestone Summary

<table>
<thead>
<tr>
<th>Key Milestone</th>
<th>Milestone Due Date</th>
<th>Milestone Status</th>
<th>Change from last quarter</th>
<th>Owner</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Begin stakeholder meetings to gather input on modifications from pilot to full time program</td>
<td>By Mar 31, 2022</td>
<td>Complete</td>
<td></td>
<td></td>
<td>APHIS held stakeholder meetings between February and April, concluding them on April 19.</td>
</tr>
<tr>
<td>Stakeholder report developed to summarize input from meetings and long-term plan for surveillance program</td>
<td>By Sep 30, 2022</td>
<td>On track</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMR surveillance pilot complete</td>
<td>Dec 31, 2022</td>
<td>On track</td>
<td></td>
<td></td>
<td>31 laboratories are enrolled for Year 5 of pilot.</td>
</tr>
<tr>
<td>Initiate long-term surveillance program</td>
<td>By Jan 31, 2023</td>
<td>On track</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tableau dashboard updated to include AMR genes identified by sequencing</td>
<td>By Dec 31, 2023</td>
<td>On track</td>
<td></td>
<td></td>
<td>Modified the AMR database to integrate it with other APHIS IT platforms and support the development of the AMR dashboard.</td>
</tr>
</tbody>
</table>
31 laboratories have been enrolled for the final year of the pilot, which runs Jan-Dec, 2022.

The number of isolates submitted in quarter 1 was slightly lower than expected, possibly due to supply chain issues. Starting in quarter 2, APHIS raised the cap on the number of isolates each laboratory can submit to the program to increase the number of samples collected and help ensure that the target of 5,000 isolates is met and that APHIS has sufficient data for representative trend analysis across the United States.

Similarly, the number of isolates submitted in Quarter 2 was also lower than anticipated. This is a consequence of the recent highly pathogenic avian influenza (HPAI) outbreak, which began in February and continues through April of 2022. Many of the laboratories participating in the AMR project have been activated for HPAI testing through the NAHLN, meaning their personnel and resources are primarily focused on supporting diagnostic testing endeavors for HPAI.
Information on how antimicrobial susceptibility testing (AST) data is generated and standards/quality control methods used for this data is found in the Year 1 report, located on the NAHLN website.

Laboratories provide monthly AST data to APHIS Veterinary Services, which is reviewed for accuracy and completeness prior to uploading to an internal APHIS VS database. From there, APHIS VS processes the data based on current Clinical and Laboratory Standards Institute (CLSI) performance standards for antimicrobial susceptibility tests and the data is inserted into the Tableau dashboard. APHIS VS and Marketing and Regulatory Programs Information Technology maintains this database and the corresponding software APHIS VS uses to manipulate the data. APHIS VS maintains the Tableau dashboard, which is accessible by the public. APHIS’ National Veterinary Services Laboratories (NVSL) or participating laboratories generate whole genome sequencing data. Participating laboratories submit data and APHIS VS evaluates it for minimum quality standards prior to being uploaded to the National Institutes of Health NCBI.
Additional information

Contributing Programs
Organizations:
  - This program is supported by participating NAHLN laboratories from the following states: AL, CA, CO, FL, GA, IA, IL, IN, KS, KY, LA, MI, MN, MO, MS, NC, ND, NE, NY, OH, PA, SD, TN, TX, WA, WI, and WY.

Program Activities:
  - This program directly contributes to the **2020-2025 National Action Plan for Combating Antibiotic-Resistant Bacteria**. It contributes to Goal 2 (Strengthen National One Health Surveillance Efforts to Combat Resistance), Objectives 1.1 (expand surveillance through existing systems to monitor antibiotic resistance from multiple sources across One Health) and Objective 1.2 (increase whole-genome sequencing and antibiotic resistance phenotypic and genotypic testing in laboratory networks for antibiotic-resistant pathogens listed in CDC’s 2019 AR Threats Report and upload sequenced data to the National Institutes of Health (NIH) National Center for Biotechnology Information (NCBI) at the National Library of Medicine or to another approved, secure, and widely accessible databases).

Policies:
  - This program directly contributes to the **USDA AMR Action Plan**. It contributes directly to Objective 2 (antibiotic drug susceptibility in food animals and meat and poultry) by providing national-level data on antibiotic susceptibility testing of selected animal pathogens.

Other Federal Activities:
  - Data collected from companion animals as part of the NAHLN AMR surveillance program is also integrated with similar data collected by FDA VetLIRN AMR surveillance program, and combined data are reported through FDA’s NARMS (National Antimicrobial Resistance Monitoring System) website.

Stakeholder / Congressional Consultations
APHIS will host regularly scheduled meetings/webinars with participating NAHLN laboratories and other external stakeholders to obtain input on the structure and interface of this AMR surveillance program with other federal surveillance programs. APHIS will incorporate input and concerns identified during these meetings, where appropriate, to improve utility of data provided and to improve efficiency of the program for participating laboratories.